AU714277B2 - Myocardial revascularization through the endocardial surface using a laser - Google Patents
Myocardial revascularization through the endocardial surface using a laser Download PDFInfo
- Publication number
- AU714277B2 AU714277B2 AU91352/98A AU9135298A AU714277B2 AU 714277 B2 AU714277 B2 AU 714277B2 AU 91352/98 A AU91352/98 A AU 91352/98A AU 9135298 A AU9135298 A AU 9135298A AU 714277 B2 AU714277 B2 AU 714277B2
- Authority
- AU
- Australia
- Prior art keywords
- myocardial revascularization
- energy
- aiming beam
- laser
- revascularization device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002107 myocardial effect Effects 0.000 title claims description 47
- 230000000250 revascularization Effects 0.000 title claims description 37
- 230000002861 ventricular Effects 0.000 claims description 40
- 210000004165 myocardium Anatomy 0.000 claims description 23
- 210000001174 endocardium Anatomy 0.000 claims description 13
- 239000013307 optical fiber Substances 0.000 claims description 10
- 230000017531 blood circulation Effects 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims 1
- 239000000835 fiber Substances 0.000 description 41
- 238000000034 method Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 9
- 210000004351 coronary vessel Anatomy 0.000 description 9
- 230000010412 perfusion Effects 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- PAXZWYXAXLLWTH-UHFFFAOYSA-N [Tm].[Cr].[Ho] Chemical compound [Tm].[Cr].[Ho] PAXZWYXAXLLWTH-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 210000001308 heart ventricle Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Laser Surgery Devices (AREA)
Description
AUSTRALIA
PATENTS ACT 1990 DIVISIONAL APPLICATION NAME OF APPLICANT(S): The Trustees of Columbia University in the City of New York e ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Little Collins Street Melbourne, 3000.
e INVENTION
TITLE:
Myocardial revascularization through the endocardial surface using a laser The following statement is a full description of this invention, including the best method of performing it known to us: Q:\OPER\EJM695783-D.309 5/11/98 -la- BACKGROUND OF TH INVENTION The present invention relates to a myocardial revascularization device and method for making channels in the inside of the heart ventricle to perfuse the myocardium.
Within this application several publications are references by arabic numerals within parentheses. Full .citations for these and other references may be found at the end of the specification immediately preceding the claims. The disclosures of all of these publications in S 15 their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
It is well known that coronary artery disease is a pervasive disease afflicting many people in this country.
Many of these people are treatable by coronary artery bypass surgery. However, alternative methods of myocardial revascularization are required for patients with coronary artery disease not amenable to coronary S 25 artery bypass. Investigators have used the CO 2 laser in arrested hearts to create transmural channels from the epicardial surface. The channels increase cardiac perfusion by shunting blood from the ventricle to myocardial sinusoids, and can endothelialize and remain patent indefinitely. In this approach, the energy is delivered from outside the ventricle, and the channels formed by the laser energy penetrate the full thickness through the ventricular wall.
-2- 00 0@ *0* 0@ 0 *0 6 So S
S
SUMMARY OF THE INVENTION It is an object of the present invention to provide an apparatus and method for myocardial revascularization to increase blood flow to the myocardium from the endocardium without using the native diseased coronary arteries.
It is an object of the present invention to provide an apparatus and method for myocardial revascularization to 10 be used with patients having extensive coronary atherosclerosis in whom bypass surgery is not possible.
It is an object of the present invention to provide an apparatus and method for myocardial revascularization which avoids forming channels which penetrate the full thickness through the ventricular wall.
The present invention provides a method for cardiac revascularization using a transendocardial approach with 20 an energy source such as a thulium-holmium-chromium:
YAG
(THC-YAG) laser. This approach can be used on a beating heart, concentrates its effects on the endocardium, which is the surface at highest risk for ischemia, and reduces potential risk of bleeding and aneurysmal formation associated with transmural channels.
According to one aspect of the invention, a method for myocardial revascularization of the heart in a patient is provided, comprising positioning a channel forming energy emitter inside the ventricle of the heart, and directing energy from the channel forming energy emitter toward the ventricular wall in an amount sufficient to form at least one channel in the ventricular wall into the myocardium to thereby increase blood flow from the endocardium to the myocardium.
The method may include the steps of positioning an aiming beam energy emitter inside the ventricle of the heart, said aiming beam energy emitter having an emitting beam which identifies the location of the emitted energy from the channel forming energy emitter, locating an aiming beam energy detector outside the heart at a position adjacent a desired channel forming site, and wherein the step of directing energy from the channel forming energy emitter is performed after the aiming beam energy detector detects aiming beam energy to thereby indicate that the channel forming energy emitter is directed to the desired channel S* forming site. The desired channel forming site may be based on familiar epicardial anatomic landmarks, such as the epicardial branches of the coronary arteries.
According to another aspect, the present invention provides a method for myocardial revascularization of the heart in a patient, comprising entering the ventricle of S the heart with a catheter having a lumen which houses a fiber which emits energy at a fiber end, locating the fiber end proximate to the ventricular wall, and emitting S energy from said fiber end in an amount sufficient to form a channel in the ventricular wall into the myocardium to thereby increase myocardial blood flow from S 25 the endocardium to the myocardium.
A myocardial revascularization device is also provided in accordance with the invention, comprising a handpiece having at least one lumen, and having an insertable end and a handling end, a fiber for carrying energy from an energy source to a fiber end from which the energy is emitted, said fiber being received in one of said lumens, means for moving the fiber within the lumen to different 92111LjtzopfAJm,15W2 9Z,3 -4stop positions, whereby the fiber end extends from the handpiece insertable end at different sites of a ventricular wall corresponding to said stop positions, and means for transmitting energy to said fiber end in an amount sufficient to form a channel in the ventricular wall into the myocardium at each of said sites, to thereby increase myocardial blood flow from the endocardium to the myocardium.
In a preferred embodiment, the present invention also provides a myocardial revascularization device, comprising: a channel forming energy emitter means, for insertion into the ventricle cavity 10 of a heart, for emitting energy to form at least one channel in the ventricular wall into the myocardium; an aiming beam energy emitter means for emitting an aiming beam which identifies the location of energy emitted from the channel forming energy emitter means; an aiming beam energy detector, for placing against the exterior of the heart, for detecting an aiming beam from the aiming beam energy emitter means; and means for energizing the channel forming energy emitter means in response to detection of an aiming beam by the aiming beam energy emitter.
S
More preferably, the present invention also provides a myocardial revascularization 20 device, comprising a channel forming energy emitter means, for insertion into the ventricle cavity of a heart, for emitting energy to form at least one channel in the ventricular wall into the myocardium, an aiming beam energy emitter means for emitting an aiming beam which identifies the location of energy emitted from the channel forming energy emitter means, an aiming beam energy detector, for placing against the exterior of the heart, for detecting an aiming beam from the aiming beam energy emitter means, and means for energizing the channel forming energy emitter means in response to detection of an aiming beam by the aiming beam energy emitter. The aiming beam energy detector location may be selected on the basis of familiar epicardial anatomic landmarks, those being the epicardial branches of the coronary arteries.
In an even more preferred embodiment the present invention provides a myocardial revascularization device for forming a channel in a desired portion of a wall of a 9 50 7 20,opeoamro 15232-93.pe,4 4Apatient's heart from within a ventricle defined by the wall, comprising; an elongated catheter having an inner lumen extending to an open distal end and means to stabilize the location of the distal end with respect to the ventricular wall said means to stabilize including means for engaging the wall of the patient's heart; an elongated optical fiber moveably disposed within the inner lumen of the catheter having a proximal end configured to receive laser energy and a distal end configured to extend out the open distal end of the catheter and to emit laser energy therefrom; and a remote source for producing laser energy optically connected to the proximal 10 end of the optical fiber.
These and other advantages will become apparent from the detailed description accompanying claims and attached drawing figures.
S
S S C *S S 95 0.O~p:pa-* aMo,15232-93.Sp,4 DESCRIPTION OF THE DRAWING Fig. 1 is a cross-sectional view of a ventricular wall of a heart, showing the epicardium, myocardium, endocardium and a channel formed by a laser energy source according to the present invention; Fig. 2A is a myocardial revascularization device according to the invention; 10 Fig. 2B shows in more detail gripping means such as suction cups on the insertable end of the catheter; o Fig. 3 shows an aiming grid to focus a transatrial laser at specific sites based on visible epicardial landmarks with the heart surgically exposed; and Fig. 4 shows a transthoracic aiming thorascope according to the invention.
o 0 0 -6- DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT According to one aspect of the invention, a method for myocardial revascularization of the heart in a patient is provided, comprising positioning a channel forming energy emitter inside the ventricle of the heart, and directing energy from the channel forming energy emitter toward the ventricular wall in an amount sufficient to form at least one channel in the ventricular wall into the myocardium to thereby increase blood flow from the endocardium to 10 the myocardium. The energy emitter may be a laser. The steps of positioning and directing are preferably repeated to form channels at different sites in the ventricular wall.
15 The method preferably includes the steps of positioning an aiming beam energy emitter inside the ventricle of the heart, said aiming beam energy emitter having an emitting beam which identifies the location of the emitted energy from the channel forming energy emitter, locating an 20 aiming beam energy detector outside the heart at a position adjacent a desired channel forming site. The channel forming site may be selected based on familiar epicardial anatomic landmarks, those being the epicardial branches of the coronary arteries. Further, the step of directing energy from the channel forming energy emitter is preferably performed after the aiming beam energy detector detects aiming beam energy to thereby indicate that the channel forming energy emitter is directed to the desired channel forming site.
The present invention also provides, in a patient, a method for myocardial revascularization of the heart, comprising entering the ventricle of the heart with a catheter having a lumen which houses a fiber which emits energy at a fiber end, locating the fiber end proximate to the ventricular vall, and emitting energy from said -7fiber end in an amount sufficient to form a channel in the ventricular wall into the myocardium to thereby increase myocardial blood flow from the endocardium to the myocardium. The fiber is preferably connected to a laser, so that the fiber end emits laser energy.
The steps of locating and emitting are preferably repeated to form channels at different sites in the ventricular wall. The step of locating preferably 10 comprises advancing the fiber end relative to the catheter a selected distance, whereby channels are formed in the ventricular wall at said selected distances.
S
S...According to another aspect of the invention, a 15 myocardial revascularization device is provided, comprising a handpiece having at least one lumen, and having an insertable end and a handling end, a fiber for carrying energy from an energy source to a fiber end from which the energy is emitted, said fiber being received in 20 one of said lumens, means for moving the fiber within the lumen to different stop positions, whereby the fiber end extends from the handpiece insertable end at different sites of a ventricular wall corresponding to said stop positions, and means for transmitting energy to said fiber end in an amount sufficient to form a channel in the ventricular wall into the myocardium at each of said sites, to thereby increase myocardial blood flow from the endocardium to the myocardium.
The means for moving the fiber preferably comprises means for moving the fiber within the lumen to different stop positions each a selected distance apart. The means for transmitting energy preferably comprises a laser. The handpiece may include means for supplying medicinal fluid, and may have means for supplying the medicinal -8fluid under pressure. The medicinal fluid may be heparin, for exam~pe.
The means for moving the fiber may comprise servomotor means for moving the fiber a selected distance, and may comprise a foot switch to activate the servomotor means.
The handpiece insertable end may include gripping means extending therefrom to grip a ventricular wall. The gripping means may comprise three suction cups.
1 According to another aspect of the invention, a myocardial revascularization device is provided, 6 c9mprising a channel forming energy emitter means, for S. insertion into the ventricle cavity of a heart, for 15 emitting energy to form at least one channel in the ventricular wall into the myocardium, an aiming beam energy emitter means for emitting an aiming beam which identifies the location of energy emitted from the channel forming energy emitter means, an aiming beam 20 energy detector, for placing against the exterior of the heart, for detecting an aiming beam from the aiming beam energy emitter means, and means for energizing the channel forming energy emitter means in response to detection of an aiming beam by the aiming beam energy emitter. The aiming beam energy detector location may be selected on the basis of familiar epicardial anatomic landmarks, those being the epicardial branches of the coronary arteries. The aiming beam energy detector may comprise an array of detector elements.
The means for energizing may comprise control means for receiving an EKG signal from a patient. The channel forming energy emitter means preferably is energized in response to detection of an aiming beam by the aiming beam energy emitter and at a suitable time in the EKG cycle.
-9- The myocardial revascularization device may comprise a magnetic element on the -hannel forming energy emitter means, and an electromagnet on the aiming beam energy detector, for electromagnetically coupling the channel forming energy emitter and detector, for stabilizing the channel forming energy emitter.
Referring now to the Figs., as shown in Fig. 1, a ventricle wall 10 has an epicardium 12, myocardium 14 and 10 endocardium 16. A laser channel 18 is also shown, which extends into the ventricle wall 10 sufficiently to communicate with the myocardium layer but which does not extend entirely through the ventricle wall to and through the epicardium. The laser channel 18 was formed using the method and apparatus according to the present invention.
t Fig. 2A shows a myocardial revascularization device according to the present invention, which can be used to 20 perform the method according to the present invention.
The device 20 comprises a catheter 22 having at least one lumen, and having an insertable end 24, and an operating end 26 to be held by a physician. An energy source, such as a laser 28, which may be a THC:YAG laser, has connected to it a fiber optic 30, which may be one or more quartz fibers. The fiber optic 30 is received through the catheter lumen and is shown having an end 32 extending from the insertable end 24 of the catheter. A servomotor 36 serves to advance the fiber end 32 to stop positions spaced certain distances from each other. The spacing may be 1 to 10 mm. for example. The servomotor 36 is connected to and controlled by a foot activator The foot activator is also connected to and controls the firing of the laser 28 when the fiber end is at the stop positions.
The device of Fig. 2A also has means for introducing medicinal fluid to the site, in the preferred form of heparin. The heparin is introduced under pressure as shown at 41 in Fig. 2A. A diaphragm 42 inside the catheter prevents the pressurized heparin from flowing out of the operating end 26 of the catheter.
As shown in Fig. 2B the insertable end 24 of the device 10 has gripping means extending therefrom in the form of S* three suction cups 44. These cups 44 provide a means to removably mount and stabilize the insertable end 24 to the inner ventricular wall, and serve as a tripod for the end 24, and the fiber end 32.
Fig. 3 shows an aiming grid and aiming beam arrangement useful for locating the desired target positions to fire the laser which creates the channels. This arrangement could be used in open chest surgery and can be used in a 20 procedure as an adjunct to coronary bypass or other procedures.
i, This arrangement comprises an aiming grid 50 having sensors in the form of photodiodes 52 located in an array on a suitable sheet material. The grid 50 is adapted to be positioned inside of the thoracic cavity adjacent the heart outside the ventricular wall in which laser channels are desired. The grid 50 is connected to a controller 54 by cable 56.
A handpiece 60, having a shell of suitable plastic material, for example, houses an aiming bean source 62.
The aiming beam source may be an 808 nm diode laser, but could also be other sources of electromagnetic, ultrasonic or magnetic energy. The aiming beam grid has sensors compatible with and adapted to detect the -11energy source. The handpiece 60 may actually be a catheter having two lumens. Also disposed in the handpiece is a fiber optic end 64 for projecting a laser beam, similar to that of Figs. 1 and 2. The fiber optic end 64 is connected, by a fiber optic 67 within the handpiece, to a laser 66 outside the handpiece. Control means to fire the laser 66 is provided in controller 66.
The controller, by way of cable 68, also provides a means to control the servomotor 70, located in the base of the 10 handpiece 60, for advancing the fiber optic end 64 to selected stop positions similarly as in Figs. 1 and 2.
r The controller 54 is also connected to receive signals S\ from a surface EKG by way of cable 72.
C
15 It is usually desired that only specific regions of the myocardium will be targets. The targets are based on the *watershed areas of each of the coronary branches, such 0 that a region poorly perfused by an occluded coronary branch would be a target, while an adjacent area might 20 not. There are virtually no visual landmarks to provide a roadmap of the coronary branches when the ventricle is viewed from the inside and even if there were, an optical system would be necessary to visually guide such a system. The coronary arteries are largely epicardial, and provide readily interpretable landmarks with which surgeons are quite familiar. The grid provides an arrangement for lining up the laser beam directly underneath the target, when the target is best identified by external landmarks.
The operation of the aiming beam grid arrangement is as follows. During open chest surgery, the grid 50 is positioned inside of the abdominal cavity adjacent the heart outside the ventricular wall in which laser channels are desired. The handpiece is inserted into the ventricular cavity and the aiming beam is nergied.
-12- When the aiming beam is sensed by the photodiode 52, indicating the proper location for a channel to be formed in the ventricular wall, the controller enables or automatically fires the laser 66. The controller also senses EKG signals and enables or automatically fires the laser only at the proper time in the heart cycle.
The handpiece is moved to different positions inside the ventricular cavity and when the aiming beam is sensed by 10 another photodiode in the grid, the laser is enabled to create another channel in the ventricular wall. This process is continued until the desired number of channels is created. The controller may be provided with circuitry to determine whether a particular photodiode 15 has previously sensed an aiming beam, so that when a channel has been created at that location, the laser will be prevented from being enabled at that location again, to thereby avoid firing the laser at a location where a channel has previously been created.
The controller may also be provided with means to detect the distance between the aiming beam source 62 (the end of the handpiece) and the grid 50, and the signal strength received. This computed distance and signal strength may be used to control the intensity of the laser energy used to create the channel and thus the size and depth thereof. The signal strength of the aiming beam received would indicate the ventricular wall thickness and dictate the channel depth desired.
The arrangement of Fig. 3 allows a physician to focus a retrograde transatrial laser at specific sites based on visible epicardial landmarks with the heart surgically exposed.
-13- Fig. 4 shows a transthoracic aiming thorascope according to the invention for focusing a percutaneously introduced laser catheter at specific sites based on epicardial landmarks. In this arrangement a single photodiode 52 is mounted at the end of a first handpiece 80 which is adapted to be inserted through adjacent ribs in the ribcage and positioned with its end against the exterior of the heart. The photodiode is connected to controller 54 by cable 50. The controller is also connected by 10 cable 68 to a servomotor 70 in a second handpiece 90. A S. laser 66 is also connected to the controller 54, which controls the laser, and its output is through a fiber optic 67, which fiber optic extends throughout the length of the second handpiece and terminating at an end 64.
The second handpiece 90 also houses an aiming beam source 62, similar to that in Fig. 3. The second handpiece may be a catheter having two lumens as in the arrangement of Fig. 3. The controller 54 receives EKG signals similarly as in Fig. 3.
*o Similarly to the operation of the device of Fig. 3, the second handpiece 90 is inserted into the ventricular cavity. The aiming beam from source 62 projects from the second handpiece 90, and when the first handpiece 80 is aligned to have photodiode 52 receive the aiming beam from the second handpiece 90, the controller enables the laser 66 to fire and create a channel in the interior ventricular wall.
An electromagnet 92 may be mounted in the end of the first handpiece 80, and a metallic ring 94 may be mounted in the second handpiece 90. Magnetic force could be used to stabilize the first handpiece end against the endocardium directly opposite the aiming scope. The first handpiece 80, sometimes referred to an aiming -14-
S.
0 10 scope, may be provided with appropriate imaging optics 96, connected to visual monitor 98, for direct visualization of the region. The details of this feature are well known to those skilled in the art.
An experiment conducted using the method according to the invention will now be described.
MATERIALS AND METHODS The left anterior descending artery (LAD) of 18 dogs laser, eight control) was ligated distal to the first diagonal, and the area at risk (AAR) was mapped with methylene blue dye. In laser animals, a catheter containing the laser fiber was passed through the left atrium, stabilized against the contracting left ventricular wall, and nontransmural channels (600 u diameter, about 4 channels/cm 2 were lasered through the endocardium (800 J pulses; frequency 3 Hz) until epicardial blanching was noted. Survivors (laser, 9/10; controls, 4/8) were sacrificed at six weeks, and the infarct size was outlined using triphenyltetrazolium chloride (TTC). Ventriculograms were done after the animals were killed by ligating the coronary arteries, clamping across the mitral and aortic valves, and instilling radiopaque dye into the ventricle.
o 0 O 0 *0 RARELT8 The AAR was similar in both groups (12.7 2.3 cm 2 vs.
13.0 3.1 cm 2 Compared with controls at six weeks, laser-treated animals had smaller infarct size (3.67 0.32 cm 2 vs. 0.73 0.13 cmW, 0.02), and lower infarct-to-AAR ratio (0.26 .05 vs. 0.06 .02, R 0.02). Neither bleeding nor aneurysms occurred in any of the animals. Ventriculograus on control animals showed no perfusion of the free vall; laser-treated animals had dye-filled sinusoids in the free wall, filling through short channels originating from the endocardial surface.
DISCUSSION
Transmural channels created with a CO 2 laser increase myocardial perfusion in experimental models, and have been used clinically as an adjunct during coronary artery bypass. Postoperative ventriculography and radionuclide scans have demonstrated perfusion, through laser 10 channels, of regions not revascularized through bypass grafts. The mechanism is thought to involve perfusion of .the collateral network of myocardial sinusoids by flow S•entering the lasered channels from the ventricular cavity during systole. The channels remain open because 15 carbonization associated with laser energy has been shown to inhibit lymphocyte, macrophage, and fibroblast migration. Thus, in contrast to channels created by needle acupuncture, laser channels heal more slowly and with less scar formation, which allows endothelialization 20 and long-term patency. Bleeding from the epicardial site of penetration is usually controlled by clot formation.
To improve myocardial perfusion, the channels must allow communication between the ventricular cavity and myocardial sinusoids, but do not need to be transmural.
In previous models, transmural channels were a consequence of the inability to deliver CO 2 laser energy through a flexible fiberoptic system, mandating application of the laser energy from the epicardial surface of the ventricle. The far-infrared (10.6 u) CO 2 laser has been used because of its ability to remove tissue precisely. The mid-infrared (2.15 u) THC:YAG laser has similar tissue effects because of a large absorption peak of water for light energy in the 2 u region. In addition, the wavelength of 2 u radiation is short enough to be effectively transmitted through low -16hydroxyl 600 u diameter quartz fibers. This feature permits application of laser energy from the endocardial surface of a beating ventricle, avoiding the need to create transmural channels from the epicardial surface.
Using this approach, the AAR in the experimental group was significantly decreased after the creation of laser channels, and after six weeks the laser animals had smaller infarcts, as measured by TTC staining. Laser- 10 treated and control animals had similar initial AAR. In the laser-treated animals, but not in the controls, ventriculography at six weeks demonstrated noncoronary perfusion of myocardial sinusoids in the area at risk through short channels communicating with the ventricular 15 chamber. There were no bleeding complications, aneurysms, or permanent arrhythmias.
In conclusion, laser energy can be transmitted through flexible quartz fibers to create myocardial channels from the endocardial surface in a beating heart. The channels improve perfusion acutely and remain patent for up to six weeks. This technique may be useful as an adjunct to coronary bypass or, with development of a delivery system, might permit percutaneous treatment of inoperable patients with diffuse coronary artery disease.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
-17-
REFEREBNCES
1. Mirhoseini M, Shelgikar S, Cayton MM: New concepts in revascularization of the myocardium. Ann Thor Surg 45:415-420, 1988.
2. Okada M, Ikuta H, Shimizu K, et al: Alternative method of myocardial revascularization by laser: Experimental and clinical study. Kobe J Med Sci 32:151- 161, 1986.
9:3. Hardy R1, Bove KE, James FW, et al: A histologic study of laser-induced transmyocardial channels. Lasers Sprg Med 6:563-573, 1987.
00.. 15 4. Oz MC, Treat MR, Trokel SL, et al: A f iberoptic compatible mid-infrared laser with C0 2 laser like effect: Application to atherosclerosis. J Surg Res 47(6):493- S. 501, 1989.
5. Treat MR, Trokel SL, Reynolds, RD, et al: A preliminary evaluation of a pulsed 2.15 micron laser for endoscopic surgery. Lasers Surg Mod 8:322-326, 1988.
Claims (1)
18- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A myocardial revascularization device for forming a channel in the ventricular wall into the myocardium of a patient's heart sufficient to increase blood flow from the endocardium to the myocardium, said device comprising: an elongated catheter having an inner lumen extending to an open distal end and means to stabilize the location of the distal end with respect to the ventricular wall of the patient's heart; (ii) an elongated optical fiber moveably disposed within the inner lumen of the catheter having a proximal end configured to receive laser energy and a distal end configured to extend out the open distal end of the catheter and to emit laser energy therefrom; and (iii) a remote source for producing laser energy optically connected to the proximal end of the optical fiber, wherein said laser energy has a wavelength which is capable of forming said channel. 2. The myocardial revascularization device according to claim 1, further comprising a motor drive unit operatively connected to the optical fiber to drive the optical fiber disposed within the inner lumen of the catheter out the distal end thereof so that the distal end of the optical fiber engages the ventricular wall to facilitate formation of a channel therein when laser energy is emitted from the distal end of the optical fiber. 3. The myocardial revascularization device according to claim 2, wherein the motor drive unit is configured to advance the optical fiber within the inner lumen of the catheter to a plurality of selected stop positions. 4. The myocardial revascularization device according to any one of claims 1 to 3, wherein the catheter further comprises means for supplying medicinal fluid. The myocardial revascularization device according to claim 4, wherein the means for supplying medicinal fluid comprises means for supplying medicinal fluid under pressure. M P:\OPER\EJH\27124-95.DIV 5/11/98 -19- 6. The myocardial revascularization device according to claim 4 or 5, wherein the medicinal fluid is heparin. 7. The myocardial revascularization device according to any one of claims 2 to 6, wherein the motor drive unit further comprises a foot switch to activate the motor drive unit. 8. The myocardial revascularization device according to any one of claims 2 to 6, wherein the plurality of selected stop positions are spaced about 1 to about 10mm apart. 00 S 9. The myocardial revascularization device according to any one of claims 1 to 8, wherein the means to stabilize comprises three suction cups. 10. The myocardial revascularization device according to any one of claims 1 to 8, further comprising: an aiming beam energy emitter means for emitting an aiming beam which identifies the location of energy emitted from the optical fiber; an aiming beam energy detector, for placing against the exterior of the heart, for detecting an aiming beam from the aiming beam energy emitter means; and means for energizing the laser energy source in response to detection of an aiming beam S by the aiming beam energy emitter. 11. The myocardial revascularization device according to claim 10, wherein the aiming beam energy detector comprises an array of detector elements. 12. The myocardial revascularization device according to claim 10 or 11, wherein the means for energizing comprises control means for receiving an EKG signal from a patient, and wherein the channel forming energy emitter means is energized in response to detection of an aiming beam by the aiming beam energy emitter and at a suitable time in the EKG cycle. 13. The myocardial revascularization device according to any one of claims 10 to 12, further I ~JI P:\OPER\EJH\27124-95.DIV 5/11/98 comprising: a magnetic element on the channel forming energy emitter means, and an electromagnet on the aiming beam energy detector, for electromagnetically coupling the channel forming energy emitter and detector, for stabilizing the channel forming energy emitter. 14. The myocardial revascularization device according to any one of claims 1 to 13, wherein the laser energy emits at a wavelength in the mid-infrared or far-infrared region of the spectrum. e* 15. The myocardial revascularization device of claim 14, wherein the laser has an energy of 0 2.15 microns. 16. A myocardial revascularization device according to any one of claims 1 to substantially as hereinbefore described with reference to the Figures and/or Examples. 0* DATED this 5th day of November, 1998 The Trustees of Columbia University in the City of New York by DAVIES COLLISON CAVE Patent Attorneys for the Applicants
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69410291A | 1991-05-01 | 1991-05-01 | |
US694102 | 1991-05-01 | ||
AU27124/95A AU695783B2 (en) | 1991-05-01 | 1995-07-21 | Myocardial revascularization through the endocardial surface using a laser |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU27124/95A Division AU695783B2 (en) | 1991-05-01 | 1995-07-21 | Myocardial revascularization through the endocardial surface using a laser |
Publications (2)
Publication Number | Publication Date |
---|---|
AU9135298A AU9135298A (en) | 1999-01-14 |
AU714277B2 true AU714277B2 (en) | 1999-12-23 |
Family
ID=25620172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU91352/98A Ceased AU714277B2 (en) | 1991-05-01 | 1998-11-05 | Myocardial revascularization through the endocardial surface using a laser |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU714277B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4658817A (en) * | 1985-04-01 | 1987-04-21 | Children's Hospital Medical Center | Method and apparatus for transmyocardial revascularization using a laser |
EP0416793A1 (en) * | 1989-08-30 | 1991-03-13 | Angeion Corporation | Catheter |
US5219347A (en) * | 1991-12-24 | 1993-06-15 | Laser Engineering, Inc. | Decoupled dual-beam control system |
-
1998
- 1998-11-05 AU AU91352/98A patent/AU714277B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4658817A (en) * | 1985-04-01 | 1987-04-21 | Children's Hospital Medical Center | Method and apparatus for transmyocardial revascularization using a laser |
EP0416793A1 (en) * | 1989-08-30 | 1991-03-13 | Angeion Corporation | Catheter |
US5219347A (en) * | 1991-12-24 | 1993-06-15 | Laser Engineering, Inc. | Decoupled dual-beam control system |
Also Published As
Publication number | Publication date |
---|---|
AU9135298A (en) | 1999-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5957916A (en) | Myocardial revascularization through the endocardial surface using a laser | |
US5607421A (en) | Myocardial revascularization through the endocardial surface using a laser | |
US6036685A (en) | Lateral- and posterior-aspect method for laser-assisted transmyocardial revascularization and other surgical applications | |
US6592576B2 (en) | Myocardial revascularization | |
US5891133A (en) | Apparatus for laser-assisted intra-coronary transmyocardial revascularization and other applications | |
US5725521A (en) | Depth stop apparatus and method for laser-assisted transmyocardial revascularization and other surgical applications | |
US5389096A (en) | System and method for percutaneous myocardial revascularization | |
AU712539B2 (en) | Methods and apparatus for myocardial revascularization | |
US6027497A (en) | TMR energy delivery system | |
US6447504B1 (en) | System for treatment of heart tissue using viability map | |
US6315774B1 (en) | Minimally invasive apparatus for forming revascularization channels | |
US5380316A (en) | Method for intra-operative myocardial device revascularization | |
JP2001509038A (en) | Percutaneous myocardial revascularization | |
CA2201670A1 (en) | Laser device for transmyocardial revascularization procedures | |
AU714277B2 (en) | Myocardial revascularization through the endocardial surface using a laser | |
AU695783B2 (en) | Myocardial revascularization through the endocardial surface using a laser | |
EP1021737B1 (en) | Apparatus for ablating tissue | |
CA2586022A1 (en) | Apparatus and method for guided ablation treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |